TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Industry Press release
Medicine Press release
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 15, 2026 23:18 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer's disease (AD) patients enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving LEQEMBI(R) therapy over an average of 17 months.
More info..
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Jul 15, 2026 23:18 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study show that nearly 83% of early Alzheimer's disease (AD) patients enrolled in the study remained stable (75.9%) or improved (6.6%) while receiving LEQEMBI(R) therapy over an average of 17 months.
More info..
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 22:51 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name:
More info..
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 22:51 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name:
More info..
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 22:21 JST
Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer's disease (AD) tau tangle pathology.
More info..
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 22:21 JST
Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer's disease (AD) tau tangle pathology.
More info..
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 15, 2026 22:21 JST
Eisai Co., Ltd. today announced the latest findings on etalanetug (development code: E2814) showed that this investigational anti-MTBR antibody reduced levels of plasma eMTBRtau243, a key biomarker of Alzheimer's disease (AD) tau tangle pathology.
More info..
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 13, 2026 23:06 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer's Association International Conference(R)
(AAIC(R)) 2026 in London support that the LEQEMBI(R) (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer's disease (AD).
More info..
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 13, 2026 23:06 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer's Association International Conference(R)
(AAIC(R)) 2026 in London support that the LEQEMBI(R) (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer's disease (AD).
More info..
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
Jul 13, 2026 23:06 JST
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that new data presented at the Alzheimer's Association International Conference(R)
(AAIC(R)) 2026 in London support that the LEQEMBI(R) (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer's disease (AD).
More info..
1
2
3
>>
Last
Releases By Industry
Business
Communications
CryptoCurrency
Financial
Industrial
Lifestyle
Medicine
Sustainablity
Technology